Glucagon-like peptide-1 (GLP-1) is a gut peptide of high clinical relevance to obesity therapy, exemplified by the FDA approval of GLP-1 analogs for weight loss. Emerging findings are unraveling the brain mechanisms through which GLP-1 analogs reduce food intake, particularly for highly palatable foods. In this session researchers will present data from both human and animal models revealing the neural mechanisms through which GLP-1 acts in the brain’s cognitive and reward circuitry to reduce food intake and body weight.

3:45pm GLP-1 and the Mesolimbic Brain Reward System
Matthew R Hayes, PhD
4:15pm GLP-1, the Lateral Septum and Food Reward
Diana L Williams, PhD
4:45pm GLP-1 Analog Treatment and the Brain Response to Food Reward
Christos Mantzoros, MD